Back to News
Market Impact: 0.12
A*STAR and Mirai Bio to Jointly Advance Research on Nucleic Acid Delivery to the Lung
Source: Business Wire
Healthcare & BiotechTechnology & Innovation
Mirai Bio and Singapore's A*STAR IMCB announced a collaboration to advance targeted nucleic-acid delivery technologies for lung epithelial and endothelial cells. The partnership supports preclinical biotech innovation but disclosed no financial terms, clinical data, commercialization timeline, or expected revenue impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- How the US midterm elections reflected resistance to data centres
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI Party isn't Ending Because Of The Blue Wave Says Ives
- SoftBank, ABB consider China carve-out to rescue $5.4bn robotics deal
- A ‘geologic freak’ called the Smackover may end America’s lithium dependence on China, and Big Oil is already there
- AI’s Grip on Financial Markets Was Never Clearer on the Way Down
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- Weekly Update: Sector Analysis, Improvements on Research Data, and Performance Enhancements
- How to Automate Equity Research Workflows: A Control-First Guide